Steve Krognes - Denali Therapeutics Treasurer Director
| DNLI Stock | USD 21.93 0.26 1.20% |
Director
Mr. Steve E. Krognes is Chief Financial Officer since October 2015 and Treasurer since November 2015. Mr. Krognes joined Denali from Genentech, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentechs Site Services organization between 2011 and 2015, and Genentechs IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers Acquisitions and a member of the Finance Executive Committee at Roche, a Swiss biotechnology company. From July 2002 to December 2003, Mr. Krognes served as Director of MA at Danske Bank based in Norway. From April 2000 to June 2002, he served as a VCist with Pylonia Ventures, a Swedish venture investments company. Prior to that, Mr. Krognes worked as a consultant at McKinsey and an investment banker at Goldman Sachs, based in London and Boston. Mr. Krognes currently serves as a member of the boards of directors of Corvus Pharmaceuticals, a biopharmaceutical company, RLS Global, a Swedish life science company, and the California Academy of Sciences, a private scientific and educational institution since 2015.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 866 8548 |
| Web | https://www.denalitherapeutics.com |
Steve Krognes Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steve Krognes against Denali Therapeutics stock is an integral part of due diligence when investing in Denali Therapeutics. Steve Krognes insider activity provides valuable insight into whether Denali Therapeutics is net buyers or sellers over its current business cycle. Note, Denali Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Denali Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steve Krognes over two weeks ago Disposition of 30000 shares by Steve Krognes of Denali Therapeutics at 20.25 subject to Rule 16b-3 | ||
Steve Krognes over six months ago Disposition of 1419 shares by Steve Krognes of Denali Therapeutics at 22.6 subject to Rule 16b-3 | ||
Steve Krognes over six months ago Disposition of 92500 shares by Steve Krognes of Denali Therapeutics at 20.5 subject to Rule 16b-3 |
Denali Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3509) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.12. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Denali Therapeutics' Asset Turnover is increasing as compared to previous years.Similar Executives
| Found 11 records | DIRECTOR Age | ||
| Soo Yu | Dominari Holdings | 54 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Stephen Connelly | Equillium | 43 | |
| Paul Clark | Agilent Technologies | 72 | |
| Sue Rataj | Agilent Technologies | 63 | |
| Mala Anand | Agilent Technologies | 53 | |
| Dow Wilson | Agilent Technologies | 61 | |
| Hans Bishop | Agilent Technologies | 56 | |
| George Scangos | Agilent Technologies | 72 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| Daniel Podolsky | Agilent Technologies | 67 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 |
Denali Therapeutics Leadership Team
Elected by the shareholders, the Denali Therapeutics' board of directors comprises two types of representatives: Denali Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Denali. The board's role is to monitor Denali Therapeutics' management team and ensure that shareholders' interests are well served. Denali Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Denali Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Chin, Senior Affairs | ||
| Carole MD, Chief Development | ||
| Mark Rowen, Vice Development | ||
| Chris Walsh, General Counsel | ||
| Ryan Watts, President CEO, Co-Founder, Director | ||
| Steve Krognes, Treasurer Director | ||
| Dana Andersen, CTO and Manufacturing Officer | ||
| Tyler Nielsen, Senior Finance | ||
| Cindy Dunkle, Chief Officer | ||
| Joe Lewcock, Chief Officer | ||
| Laura Hansen, Vice Relations | ||
| Chris JD, General Counsel | ||
| Alexander MD, CFO, CoFounder | ||
| Marc TessierLavigne, Chairman CoFounder | ||
| Tony Estrada, Senior Sciences | ||
| Katie Peng, Chief Officer |
Denali Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Denali Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 2.33 B | ||||
| Shares Outstanding | 143.92 M | ||||
| Shares Owned By Insiders | 9.66 % | ||||
| Shares Owned By Institutions | 91.44 % | ||||
| Number Of Shares Shorted | 7.84 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.37 X | ||||
| Price To Sales | 3,339 X |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.